Related by context. Frequent words. (Click for all words.) 63 dose escalation trial 61 multicenter randomized 61 double blinded placebo 60 multicentre 60 active comparator 60 PRECiSE 59 label multicenter 58 randomized Phase III 58 prospective randomized controlled 58 multicenter clinical 58 label dose escalation 57 dose escalation 57 blinded placebo controlled 56 Phase III randomized 56 placebo controlled clinical 56 noninferiority 56 phase IIb 56 prospective randomized 56 dose escalation study 55 placebo controlled 55 Phase Ib clinical 55 randomized controlled clinical trials 55 Phase Ia 55 MIRCERA 55 unblinded 55 multicenter randomized double 55 Phase 2a trial 55 randomized controlled 55 Amrubicin 54 phase IIa 54 Phase 2b study 54 placebo controlled randomized 54 Phase 1b 54 Phase Ib 54 nab paclitaxel 54 randomized placebo controlled 53 safety tolerability pharmacokinetics 53 relapsed refractory multiple myeloma 53 randomized controlled clinical 53 phase 2a 53 pharmacodynamic effects 53 administered subcutaneously 53 irbesartan 53 RRMS patients 53 blind randomized controlled 53 Phase 1b trial 53 confirmatory Phase III 53 single ascending dose 53 Phase 2a clinical 53 tolerated dose MTD 53 randomized 53 multicenter 52 Multicenter 52 Phase 1b clinical 52 prospective observational 52 mg QD 52 blind placebo controlled 52 talabostat 52 placebo controlled studies 52 Phase III pivotal 52 Phase III 51 Phase IIa 51 non inferiority 51 Phase II 51 blind randomized 51 peginterferon alfa 2b 51 Phase IIa clinical 51 Phase IIa trial 51 IPX# 51 Board DSMB 51 PA# [002] 51 Phase 1a 51 pertuzumab 51 multiple ascending dose 51 randomized clinical 51 dose regimens 50 blind randomized placebo 50 chemoradiotherapy 50 Phase 2a 50 glatiramer acetate 50 randomized #:# 50 metastatic hormone refractory 50 SCH # 50 ZD# [001] 50 anticancer compound 50 unblinding 50 TRITON TIMI 50 pivotal Phase III 50 prespecified 50 plus dexamethasone 50 BAY #-# 50 LIALDA 50 COPAXONE R 50 Rosuvastatin 50 eszopiclone 50 dacarbazine 49 randomized Phase 49 Phase 2b trial 49 double blind placebo 49 NSABP 49 temsirolimus